Arkema Reports Mixed Q1 2026 Results Amid Middle East Crisis…

Event summary

Arkema reported stable volumes year-over-year, with a 1.5% increase in Specialty Materials volumes driven by March improvement.
EBITDA declined 14% year-over-year to €283 million, impacted by a €20 million unfavorable currency effect.
Sales dropped 8.4% to €2,182 million, with a negative 5.1% currency effect primarily from the US dollar devaluation.
Key attractive markets like batteries, sports, 3D printing, and healthcare grew around 15% year-over-year.
The company confirmed its target of slight EBITDA growth at constant currencies for 2026 despite Middle East crisis impacts.

The big picture

Arkema's Q1 2026 results reflect the broader challenges faced by the chemical industry amid geopolitical tensions and currency fluctuations. The company's focus on key attractive markets and operational resilience highlights its strategic shift towards Specialty Materials. However, the Middle East crisis poses significant risks to supply chains and input costs, requiring agile adjustments in pricing and supply chain management.

What we're watching

Geopolitical Impact: How the Middle East crisis will affect global demand, input costs, and supply disruptions for Arkema.
Pricing Strategy: Whether Arkema's pricing actions can effectively offset high inflation of input costs.
Segment Performance: The pace at which Advanced Materials and Adhesive Solutions segments recover in Q2 2026.